Pharmaxis shares dive 30% on trial results
Pharmaceutical company, Pharmaxis (ASX:PXS) underwhelmed the market with the results from their phase III clinical trial of cystic fibrosis treatment drug Bronchitol®.
- Insights: CSO Security Capabilities Survey 2019
- The NDB scheme ferreted out nearly 1000 data breaches in its first year. Now, the harder part begins.
- Executives’ dismissive cybersecurity attitudes set the stage for Toyota, Cabrini, Parliament, and other breaches
- A third of Chrome extensions use libraries with known vulnerabilities, a handy new tool finds
- Cisco warns on Hyperflex security vulnerabilities